How the Patient Perspective Led to a Hemophilia Medical Breakthrough

Please see https://www.pfi.sr/HYMPAVZI_PI  for Full PI​

#HYMPAVZISponsored William S. Somers, Ph.D. is a biotherapeutics research and development leader with more than 30 years of experience across biotechnology and pharmaceutical organizations, including Pfizer.​

As a scientist living with hemophilia, Dr. Somers played a key role in driving the patient-centric and purposeful design of HYMPAVZI (marstacimab-hncq). This episode will explore how the patient perspective influenced the scientific journey, with a special focus on Will’s research and why it was personally important for him to bring HYMPAVZI to people with hemophilia. To learn more and for safety information, visit HYMPAVZI.com.​

This post is directed to a U.S. audience and may not be suitable outside of the U.S. This video is intended to be viewed as it was originally produced in partnership with Pfizer. Remember, this content is for educational purposes only and is not intended to replace discussions with a healthcare provider.​

PP-HYM-USA-1071​

Show Notes:​

For prescribing information visit pfi.sr/HYMPAVZI_PI​

For information on how to navigate your treatment journey visit the shared decision-making guide here.

Listen and subscribe where you get your podcasts!​

#Hemophilia

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use HYMPAVZI safely and effectively. See full prescribing information for HYMPAVZI.

HYMPAVZI (marstacimab-hncq) injection, for subcutaneous use
Initial U.S. Approval: 2024

INDICATIONS AND USAGE

HYMPAVZI is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with:

hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or

hemophilia B (congenital factor IX deficiency) without factor IX inhibitors.

DOSAGE AND ADMINISTRATION

See Full Prescribing Information for important dosing and administration instructions. 

The recommended dosage of HYMPAVZI is:

Loading dose: 300 mg (two 150 mg injections) by subcutaneous injection

Maintenance dose: One week after the loading dose, initiate maintenance dosing of 150 mg every week by subcutaneous injection on the same day each week, at any time of day.

Dose adjustment to 300 mg subcutaneous injection weekly can be considered.

Factor VIII and factor IX products can be administered for the treatment of breakthrough bleeds in patients receiving HYMPAVZI. Do not use additional doses of HYMPAVZI to treat breakthrough bleeds. 

Temporarily discontinue HYMPAVZI before major surgery. 

DOSAGE FORMS AND STRENGTHS

Injection: 150 mg/mL in a single-dose prefilled syringe 

Injection: 150 mg/mL in a single-dose prefilled pen 

CONTRAINDICATIONS

None.

WARNINGS AND PRECAUTIONS

Thromboembolic Events: Thromboembolic events may occur. Interrupt HYMPAVZI prophylaxis if symptoms occur.

Hypersensitivity: Hypersensitivity reactions may occur. In the event of a severe allergic reaction, discontinue HYMPAVZI.

Embryofetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and to use effective contraception.

ADVERSE REACTIONS

Adverse reactions reported in ≥3% of HYMPAVZI-treated patients were injection site reaction, headache, and pruritus. 

To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 12/2025